…
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Innovation Pharmaceuticals Inc is an OTC Pink–listed, development-stage pharmaceutical company with limited public disclosure; it appears positioned to develop novel anti-infective and anti-inflammatory therapeutics. Major long-term growth drivers may include clinical trial progress, regulatory approvals, and successful licensing or commercialization agreements, which could support increased revenue and pipeline value. Investors may find the company attractive for potential upside if programs advance and address unmet medical needs.
The most important investment risks are high probability of clinical and regulatory failure, scarce public information and low liquidity, recurring financing needs, and execution risk typical for small biopharmaceutical developers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -3.17M | -7.04M | -13.87M | -6.65M | -8.68M |
| Net income | -3.17M | -7.04M | -13.87M | -6.65M | -8.68M |
| Selling general administrative | 1.48M | 1.96M | 2.00M | 2.27M | 2.11M |
| Reconciled depreciation | 0.37M | 0.38M | 0.38M | 0.37M | 0.37M |
| Ebit | -2.94M | -6.76M | -9.02M | -4.63M | -6.30M |
| Ebitda | - | -6.54M | -8.64M | -6.01M | -6.11M |
| Operating income | -2.94M | -6.76M | -9.02M | -4.63M | -6.45M |
| Interest expense | 0.06M | 0.12M | 4.86M | 0.26M | 2.20M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | - | - | - | 0.00M |
| Net interest income | -0.06M | -0.12M | -4.86M | -0.26M | -2.20M |
| Total revenue | 0.00M | 0.02M | 0.00M | 0.42M | 0.00M |
| Total operating expenses | 2.94M | 6.78M | 9.02M | 5.06M | 6.45M |
| Total other income expense net | -0.17M | -0.17M | - | -1.75M | -0.03M |
| Net income from continuing ops | -3.17M | -7.04M | -13.87M | -6.65M | -8.68M |
| Net income applicable to common shares | -3.17M | -7.04M | -13.87M | -6.65M | -8.68M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 7.52M | 10.38M | 14.30M | 9.25M | 4.05M |
| Intangible assets | 2.00M | 2.31M | 2.75M | 3.06M | 3.34M |
| Other current assets | 0.12M | - | - | - | - |
| Total liab | 5.48M | 5.65M | 6.79M | 7.79M | 8.18M |
| Total stockholder equity | 2.04M | 4.73M | 7.51M | 1.46M | -4.13M |
| Deferred long term liab | - | 0.06M | 0.78M | - | - |
| Other current liab | 1.49M | 1.55M | 1.50M | 1.50M | 1.49M |
| Common stock | 0.05M | 0.05M | 0.04M | 0.03M | 0.02M |
| Capital stock | 0.05M | 0.05M | 0.04M | 0.03M | 0.02M |
| Retained earnings | -125.33M | -122.16M | -115.12M | -101.24M | -94.60M |
| Other assets | 0.08M | 0.14M | 0.86M | 0.08M | 0.08M |
| Cash | 1.52M | 3.81M | 10.19M | 6.02M | 0.58M |
| Total current liabilities | 5.02M | 4.81M | 6.54M | 7.37M | 7.30M |
| Net debt | - | - | - | - | 1.34M |
| Short term debt | - | - | - | - | 1.92M |
| Short long term debt | 0.21M | 0.25M | 1.46M | 1.90M | 1.92M |
| Property plant equipment | - | - | - | - | 0.00M |
| Total current assets | 1.63M | 3.95M | 10.69M | 6.11M | 0.62M |
| Long term investments | 3.81M | 3.98M | - | - | - |
| Net tangible assets | 0.04M | 2.42M | 4.75M | -1.60M | -7.47M |
| Long term debt | - | - | - | - | 0.88M |
| Accounts payable | 1.50M | 1.08M | 1.08M | 0.56M | 0.64M |
| Non currrent assets other | - | - | - | - | 3.42M |
| Non current assets total | 5.88M | 6.43M | 3.61M | 3.14M | 3.42M |
| Capital lease obligations | 0.06M | 0.25M | 0.42M | 0.56M | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -0.06M | -4.00M | -4.00M | -4.00M | -4.00M |
| Change to liabilities | 0.42M | 0.00M | 0.52M | -0.08M | -1.06M |
| Total cashflows from investing activities | -0.06M | -4.08M | -0.07M | -0.09M | -0.05M |
| Net borrowings | -0.04M | -1.03M | -0.20M | -0.20M | -0.20M |
| Total cash from financing activities | -0.12M | 3.97M | 13.74M | 9.69M | 4.53M |
| Change to operating activities | -0.11M | -0.38M | -1.37M | -0.03M | -0.19M |
| Net income | -3.17M | -7.04M | -13.87M | -6.65M | -8.68M |
| Change in cash | -2.29M | -6.39M | 4.18M | 5.44M | -1.84M |
| Begin period cash flow | 3.81M | 10.19M | 6.02M | 0.58M | 2.42M |
| End period cash flow | 1.52M | 3.81M | 10.19M | 6.02M | 0.58M |
| Total cash from operating activities | -2.11M | -6.28M | -9.49M | -4.16M | -6.33M |
| Issuance of capital stock | - | 0.00M | 9.59M | 0.00M | 1.89M |
| Depreciation | 0.37M | 0.38M | 0.38M | 0.40M | 0.37M |
| Dividends paid | 0.09M | 0.09M | 0.09M | 0.09M | - |
| Sale purchase of stock | - | 0.00M | -0.67M | -0.06M | -0.09M |
| Change to netincome | 0.38M | 0.75M | 4.85M | 2.21M | 3.22M |
| Capital expenditures | 0.06M | 0.08M | 0.07M | 0.09M | 0.09M |
| Change in working capital | 0.31M | -0.37M | -0.85M | -0.11M | -1.25M |
| Stock based compensation | 0.21M | 0.58M | 0.18M | 0.43M | 1.08M |
| Other non cash items | - | 0.18M | 4.66M | -0.05M | 2.03M |
| Free cash flow | -2.17M | -6.36M | -9.57M | -4.25M | -6.42M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IPIX Innovation Pharmaceuticals Inc |
- -% |
0.00 | - | - | 409.17 | 1.78 | 202.69 | -0.66 |
| NVO Novo Nordisk A/S |
-0.54 1.36% |
38.90 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
520.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.34 0.25% |
923.34 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Leo Ehrlich CPA | Chairman, CEO, CFO, Principal Accounting Officer & Sec. | 1958 |
| Ms. Jane Harness M.S., MP, MS | Sr. VP of Clinical Sciences & Portfolio Management | 1968 |
| Dr. W. James Alexander | Consultant | 1950 |
| Mr. Jim Boeheim | Bus. Advisor | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.